Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates

ACS Medicinal Chemistry Letters

Volumn 7, Issue 11, 2016, Pages 988-993

  Zhang, Donglu ^a   Pillow, Thomas H ^b   Ma, Yong ^a   Cruz Chuh, Josefa Dela ^c   Kozak, Katherine R ^c   Sadowsky, Jack D ^d   Lewis Phillips, Gail D ^e   Guo, Jun ^e   Darwish, Martine ^d   Fan, Peter ^a   Chen, Jingtian ^f   He, Changrong ^f   Wang, Tao ^f   Yao, Hui ^f   Xu, Zijin ^f   Chen, Jinhua ^f   Wai, John ^f   Pei, Zhonghua ^b   Hop, Cornelis E C A ^a   Khojasteh, S Cyrus ^a   Dragovich, Peter S ^b   more..

^a Departments of Pharmacokinetics and Drug Metabolism   (United States)

^b Discovery Chemistry   (United States)

^c Genentech   (United States)

^d Protein Analytical Chemistry   (United States)

^e GENENTECH INC   (United States)

^f WUXI APPTEC   (China)

Author keywords

Antibody drug conjugate; cancer; disulfide linker; linker immolation; pyrrolobenzodiazepine

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BETA MERCAPTOETHYL CARBAMATE DISULFIDE; CD22 ANTIGEN; DISULFIDE; MONOCLONAL ANTIBODY; PYRROLOBENZODIAZEPINE CD22 ANTIBODY CONJUGATE; PYRROLO[2,1 C][1,4]BENZODIAZEPINE DERIVATIVE; THIOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BJAB CELL LINE; CELL KILLING; CELL LINE; CONTROLLED STUDY; DNA ALKYLATION; DRUG CONJUGATION; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERACTIONS WITH DNA; PRIORITY JOURNAL; WSU DLCL2 CELL LINE;

EID: 84994905093     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00233     Document Type: Article

References (29)

1. LoRusso, P. M.; Weiss, D.; Guardino, E.; Girish, S.; Sliwkowski, M. X. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer Clin. Cancer Res. 2011, 17, 6437-6447 10.1158/1078-0432.CCR-11-0762
2. Senter, P. D.; Sievers, E. L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 2012, 30, 631-637 10.1038/nbt.2289
3. Chari, R. V. J.; Miller, M. L.; Widdison, W. C. Antibody-drug conjugates: An emerging concept in cancer therapy Angew. Chem., Int. Ed. 2014, 53, 3796-3827 10.1002/anie.201307628
4. Saunders, L. R.; Bankovich, A. J.; Anderson, W. C.; Aujay, M. A.; Bheddah, S.; Black, K.; Desai, R.; Escarpe, P. A.; Hampl, J.; Laysang, A.; Liu, D.; Lopez-Molina, J.; Milton, M.; Park, A.; Pysz, M. A.; Shao, H.; Slingerland, B.; Torgov, M.; Williams, S. A.; Foord, O.; Howard, P.; Jassem, J.; Badzio, A.; Czapiewski, P.; Harpole, D. H.; Dowlati, A.; Massion, P. P.; Travis, W. D.; Pietanza, M. C.; Poirier, J. T.; Rudin, C. M.; Stull, R. A.; Dylla, S. J. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo Sci. Transl. Med. 2015, 7, 302ra136 10.1126/scitranslmed.aac9459
5. Sutherland, M. S. K.; Sanderson, R. J.; Gordon, K. A.; Andreyka, J.; Cerveny, C. G.; Yu, C.; Lewis, T. S.; Meyer, D. L.; Zabinski, R. F.; Doronina, S. O.; Senter, P. D.; Law, C. L.; Wahl, A. F. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates J. Biol. Chem. 2006, 281, 10540-10547 10.1074/jbc.M510026200
6. Jeffrey, S. C.; Burke, P. J.; Lyon, R. P.; Meyer, D. W.; Sussman, D.; Anderson, M.; Hunter, J. H.; Leiske, C. I.; Miyamoto, J. B.; Nicholas, N. D.; Okeley, N. M.; Sanderson, R. J.; Stone, I. J.; Zeng, W.; Gregson, S. J.; Masterson, L.; Tiberghien, A. C.; Howard, P. W.; Thurston, D. E.; Law, C. L.; Senter, P. D. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology Bioconjugate Chem. 2013, 24, 1256-1263 10.1021/bc400217g
7. Junutula, J. R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D. D.; Weir, S.; Chen, Y.; Simpson, M.; Tsai, S. P.; Dennis, M. S.; Lu, Y.; Meng, Y. G.; Ng, C.; Yang, J.; Lee, C. C.; Duenas, E.; Gorrell, J.; Katta, V.; Kim, A.; McDorman, K.; Flagella, K.; Venook, R.; Ross, S.; Spencer, S. D.; Lee Wong, W.; Lowman, H. B.; Vandlen, R.; Sliwkowski, M. X.; Scheller, R. H.; Polakis, P.; Mallet, W. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 2008, 26, 925-932 10.1038/nbt.1480
8. Junutula, J. R.; Flagella, K. M.; Graham, R. A.; Parsons, K. L.; Ha, E.; Raab, H.; Bhakta, S.; Nguyen, T.; Dugger, D. L.; Li, G.; Phillips, G. D. L.; Hiraragi, H.; Fuji, R. N.; Tibbitts, J.; Vandlen, R.; Spencer, S. D.; Scheller, R. H.; Polakis, P.; Sliwkowski, M. X. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target HER2-positive breast cancer Clin. Cancer Res. 2010, 16, 2-5 10.1158/1078-0432.CCR-10-0987
9. Erickson, H. K.; Lambert, J. M. ADME of antibody-maytansinoid conjugates AAPS J. 2012, 14, 799-805 10.1208/s12248-012-9386-x
10. McCombs, J. R.; Owen, S. C. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry AAPS J. 2015, 17, 339-351 10.1208/s12248-014-9710-8
11. Jain, N.; Smith, S. W.; Ghone, S.; Tomczuk, B. Current ADC Linker Chemistry Pharm. Res. 2015, 32, 3526-3540 10.1007/s11095-015-1657-7
12. Doronina, S. O.; Toki, B. E.; Torgov, M. Y.; Mendelsohn, B. A.; Cerveny, C. G.; Chace, D. F.; DeBlanc, R. L.; Gearing, R. P.; Bovee, T. D.; Siegall, C. B.; Francisco, J. A.; Wahl, A. F.; Meyer, D. L.; Senter, P. D. Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 2003, 21, 778-784 10.1038/nbt832
13. Kellogg, B. A.; Garrett, L.; Kovtun, Y.; Lai, K. C.; Leece, B.; Miller, M.; Payne, G.; Steeves, R.; Whiteman, K. R.; Widdison, W.; Xie, H.; Singh, R.; Chari, R. V. J.; Lambert, J. M.; Lutz, R. J. Disulfide-linked antibody-maytansinoid conjugates: Optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage Bioconjugate Chem. 2011, 22, 717-727 10.1021/bc100480a
14. Ricart, A. D. Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin Clin. Cancer Res. 2011, 17, 6417-6427 10.1158/1078-0432.CCR-11-0486
15. Pillow, T.; Sadowsky, J.; Zhang, D.; Yu, S. F.; Del Rosario, G.; Xu, K.; He, J.; Bhakta, S.; Ohri, R.; Kozak, K. R.; Ha, E.; Junutula, J. R.; Flygare, J. A. Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates Chem. Sci. 2016, 10.1039/C6SC01831A
16. Erickson, H. K.; Park, P. U.; Widdison, W. C.; Kovtun, Y. V.; Garrett, L. M.; Hoffman, K.; Lutz, R. J.; Goldmacher, V. S.; Blättler, W. A. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res. 2006, 66, 4426-4433 10.1158/0008-5472.CAN-05-4489
17. Kung Sutherland, M. S.; Walter, R. B.; Jeffrey, S. C.; Burke, P. J.; Yu, C.; Kostner, H.; Stone, I.; Ryan, M. C.; Sussman, D.; Lyon, R. P.; Zeng, W.; Harrington, K. H.; Klussman, K.; Westendorf, L.; Meyer, D.; Bernstein, I. D.; Senter, P. D.; Benjamin, D. R.; Drachman, J. G.; McEarchern, J. A. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML Blood 2013, 122, 1455-1463 10.1182/blood-2013-03-491506
18. Jenkins, T. C.; Hurley, L. H.; Neidle, S.; Thurston, D. E. Structure of a covalent DNA minor groove adduct with a pyrrolobenzodiazepine dimer: evidence for sequence-specific interstrand cross-linking J. Med. Chem. 1994, 37, 4529-4537 10.1021/jm00052a012
19. Rahman, K. M.; James, C. H.; Thurston, D. E. Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers Nucleic Acids Res. 2011, 39, 5800-5812 10.1093/nar/gkr122
20. Rahman, K. M.; Thompson, A. S.; James, C. H.; Narayanaswamy, M.; Thurston, D. E. The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links J. Am. Chem. Soc. 2009, 131, 13756-13766 10.1021/ja902986x
21. Petrusek, R. L.; Anderson, G. L.; Garner, T. F.; Fannin, Q. L.; Kaplan, D. J.; Zimmer, S. G.; Hurley, L. H. Pyrrol[1,4]benzodiazepine antibiotics. Proposed structures and characteristics of the in vitro deoxyribonucleic acid adducts of anthramycin, tomaymycin, sibiromycin, and neothramycins A and B Biochemistry 1981, 20, 1111-1119 10.1021/bi00508a011
22. Hartley, J. A. The development of pyrrolobenzodiazepines as antitumour agents Expert Opin. Invest. Drugs 2011, 20, 733-744 10.1517/13543784.2011.573477
23. Brülisauer, L.; Gauthier, M. A.; Leroux, J.-C. J. Disulfide-containing parenteral delivery systems and their redox-biological fate J. Controlled Release 2014, 195, 147-154 10.1016/j.jconrel.2014.06.012
24. Singh, R.; Whitesides, G. M. Thiol-disulfide interchange Suppl. S. Chem. Sulfur-containing Funct. Groups 1993, 633-658 10.1002/9780470034408.ch13
25. Freter, R.; Pohl, E. R.; Wilson, J. M.; Hupe, D. J. Role of the central thiol in determining rates of the thiol-disulfide interchange reaction J. Org. Chem. 1979, 44, 1771-1774 10.1021/jo01325a005
26. Jung, M. E.; Piizzi, G. gem-disubstituent effect: theoretical basis and synthetic applications Chem. Rev. 2005, 105, 1735-1766 10.1021/cr940337h
27. Thurston, D. E.; Vassoler, H.; Jackson, P. J.; James, C. H.; Rahman, K. M. Effect of hairpin loop structure on reactivity, sequence preference and adduct orientation of a DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour agent Org. Biomol. Chem. 2009, 13, 4031-4040 10.1039/C4OB02405B
28. Polson, A. G.; Williams, M.; Gray, A. M.; Fuji, R. N.; Poon, K. A.; McBride, J.; Raab, H.; Januario, T.; Go, M.; Lau, J.; Yu, S.-F.; Du, C.; Fuh, F.; Tan, C.; Wu, Y.; Liang, W.-C.; Prabhu, S.; Stephan, J.-P.; Hongo, J.; Dere, R. C.; Deng, R.; Cullen, M.; de Tute, R.; Bennett, F.; Rawstron, A.; Jack, A.; Ebens, A. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma Leukemia 2010, 24, 1566-1573 10.1038/leu.2010.141
29. Zhang, D.; Yu, S. F.; Ma, Y.; Xu, K.; Dragovich, P. S.; Pillow, T. H.; Liu, L.; Del Rosario, G.; He, J.; Pei, Z.; Sadowsky, J. D.; Erickson, H. K.; Hop, C. E. C. A.; Khojasteh, S. C. Chemical structure and concentration of intratumor catabolites determine the efficacy of antibody drug conjugate Drug Metab. Dispos. 2016, 44, 1517-1523 10.1124/dmd.116.070631